Antiviral Treatment for Hepatitis C Virus Infection after Liver Transplantation
Antiviral Treatment for Hepatitis C Virus Infection after Liver Transplantation
复制标题
肝移植术后丙型肝炎病毒感染的抗病毒治疗
DOI：
--
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
N. Kokudo
中科院分区：
文献类型：
--
作者：
Y. Sugawara;S. Tamura;N. Kokudo
很大一部分慢性丙型肝炎病毒（HCV）感染的患者在20 - 30年内发展为肝硬化和终末期肝病并发症，需要肝移植，然而，再感染是常见的，并在免疫抑制下导致进一步的不良事件。由于耐受性差，移植前抗病毒或抢先治疗仅限于轻度失代偿患者。治疗的主要手段是在有证据表明慢性丙型肝炎复发后进行定向抗病毒治疗。聚乙二醇干扰素和利巴韦林联合治疗是目前的标准治疗，持续病毒应答率为25%至45%。该比率低于免疫功能正常人群，部分原因是不耐受的患病率较高。到目前为止，对于晚期肝病患者和肝移植后HCV的抗病毒治疗方式、时间或剂量尚无普遍共识。新的抗HCV药物来延缓疾病进展或增强病毒清除是必要的。
A significant proportion of patients with chronic hepatitis C virus (HCV) infection develop liver cirrhosis and complications of end-stage liver disease over two to three decades and require liver transplantation, however, reinfection is common and leads to further adverse events under immunosuppression. Pretransplant antiviral or preemptive therapy is limited to mildly decompensated patients due to poor tolerance. The mainstay of management represents directed antiviral therapy after evidence of recurrence of chronic hepatitis C. Combined pegylated interferon and ribavirin therapy is the current standard treatment with sustained viral response rates of 25% to 45%. The rate is lower than that in the immunocompetent population, partly due to the high prevalence of intolerability. To date, there is no general consensus regarding the antiviral treatment modality, timing, or dosing for HCV in patients with advanced liver disease and after liver transplantation. New anti-HCV drugs to delay disease progression or to enhance viral clearance are necessary.
影响因子：
29.4
作者：
Lyra, AC;Fan, XF;Di Bisceglie, AM
通讯作者：
Di Bisceglie, AM
影响因子：
29.4
作者：
Forman, LM;Lewis, JD;Lucey, MR
通讯作者：
Lucey, MR
影响因子：
29.4
作者：
McHutchison, JG;Manns, M;Albrecht, JK
通讯作者：
Albrecht, JK